# **Emerging Treatments**

## Percutaneous Peripheral Nerve Stimulation High Frequency Block

John Chae, MD

Exploring the Treatment and Management of Chronic Pain and Implications for Disability Determination

National Academies of Science, Engineering and Medicine

April 17-18, 2025





### Disclosures

- Co-inventor of Percutaneous Peripheral Nerve Stimulation
- Patents
- Consultant to SPR Therapeutics
- Ownership interest in SPR Therapeutics





Percutaneous Peripheral Nerve Stimulation


Hemiplegic Shoulder Pain

- Percutaneous electrode(s)
   anchored in deltoid, a muscle
   surrounding the painful shoulder
- External stimulator: stimulate the motor branches of axillary nerve to the deltoid

### Muscle contraction


- Afferent feedback to central nervous system
- Treat for 30-60 days
- Remove lead(s)













## Percutaneous Peripheral Nerve Stimulation Hemiplegic Shoulder Pain

#### RESEARCH ARTICLE

# Intramuscular Electrical Stimulation for Hemiplegic Shoulder Pain

A 12-Month Follow-Up of a Multiple-Center, Randomized Clinical Trial ORIGINAL RESEARCH ARTICLE

Peripheral Nerve Stimulation Compared with Usual Care for Pain Relief of Hemiplegic Shoulder Pain

A Randomized Controlled Trial

ABST Chae

Zorow

hemipl clinical 1. Pain relief and reduction in pain interference that persist after end of treatment (lead removal)


mulation pain: a

- 2. Postulated mechanism
  - -Afferent feedback to central nervous system
  - -Modulation of central sensitization





# Contralaterally Controlled FES (CCFES)




By participating in CCFES mediated functional tasks, activity dependent neuroplasticity is induced to facilitate motor recovery.












Electrical
Stimulation-mediated
Activity-dependent
Neuroplasticity




Electrical Stimulation-mediated Activity-dependent Neuroplasticity

BASELINE




Electrical
Stimulation-mediated
Activity-dependent
Neuroplasticity

AFTER
TREATMENT
(90 Days)













### Beyond Hemiplegic Shoulder Pain...

- If central sensitization is the convergent mechanism for chronic musculoskeletal pain in general, and...
- If percutaneous PNS reduces hemiplegic shoulder pain via modulation of central sensitization...
- Then, percutaneous PNS should reduce chronic musculoskeletal pain in general...















# Percutaneous Peripheral Nerve Stimulation Multiple Clinical Indications







Responder Rate ≥50% pain relief and/or Improvement on PGIC




# Percutaneous Peripheral Nerve Stimulation Multiple Clinical Indications




## High Frequency Block


















# High Frequency Block



elived: May 31, 2034 Revised: August 19, 2024 Accepted: August 30, 2024

https://doi.org/10.1016/j.neurom.2024.08.010

#### **Long-Term Treatment of Chronic** Postamputation Pain With Bioelectric Nerve Block: Twelve-Month Results of the Randomized, Double-Blinded, Cross-Over **QUEST Study**

Leonardo Kapural, MD, PhD<sup>1</sup> o; Billy Kim, MD<sup>2</sup>; John Eidt, MD<sup>3</sup>; Erika A. Petersen, MD<sup>4</sup>; Jason M. Schwalb, MD<sup>5</sup>; Konstantin V. Slavin, MD<sup>6,7</sup>; Nagy Mekhail, MD, PhD8

#### ABSTRACT

Objective: The multicenter, randomized, double-blinded, active-sham controlled trial (high-freQUEncy nerve block for poST amputation pain [QUEST]) was conducted to show the safety and efficacy of a novel, peripherally placed high-frequency nerve block (HFNB) system in treating chronic postamputation pain (PAP) in patients with lower limb amputations. The primary outcomes from QUEST were reported previously. This study presents the long-term, single-cross-over, secondary outcomes of ondemand HFNB treatment for chronic PAP.

Materials and Methods: After the three-month randomized period, subjects in the active-sham group were crossed over to receive therapy for 12 months. Subjects self-administered HFNB therapy as needed and reported their pain (numerical rating scale (NRS); range, 1-10) before and 30 and 120 minutes after each treatment. Pain medication use was reported throughout the study. Pain-days per week and quality of life (QOL) were assessed using the Brief Pain Inventory (BPI). Adverse events (AEs) were recorded for all subjects implanted for 12 months.

Results: Of 180 subjects implanted in QUEST, 164 (91%) were included in the cross-over period, and 146 (82%) completed followup. By month 12, average NRS pain in the combined cohort was reduced by 2.3 ± 2.2 points (95% CI, 1.7-2.8; p < 0.0001) 30 minutes after treatment and 2.9 ± 2.4 points (95% CI, 2.2-3.6; p < 0.0001) 120 minutes after treatment. Mean pain-days per week were significantly reduced (-3.5  $\pm$  2.7 days; p < 0.001), and subject daily opioid use was reduced by 6.7  $\pm$  29.0 morphine equivalent dose from baseline to month 12 (p = 0.013). Mean BPI-interference scores (QQL) improved by 2.7  $\pm$  2.7 points from baseline (p < 0.001). The incidence of nonserious AEs and serious AEs was 72% (130/180) and 42% (76/180), respectively; serious device-related AEs occurred in 15 of 180 subjects (8%).

Conclusion: Overall, HFNB delivered directly to the damaged peripheral nerve provided sustained, on-demand relief of acute PAP exacerbations, reduced opioid utilization, and improved QOL for patients with lower limb amputations with chronic PAP.

Keywords: High-frequency nerve block, neuropathic pain, peripheral nerve stimulation, phantom limb pain, postamputation pain

Address correspondence to: Leonardo Kapural, MD, PhD, Carolinas Pain Institute and Center for Clinical Research, 145 Kimel Park Drive #200, Winston-Salem, NC 27103, USA, Email: (kapuralmd@gmail.com

- Carolinas Pain Institute and Center for Clinical Research, Winston-Salem, NC, USA;
- Department of Vascular Surgery, The Surgical Clinic, Nashville, TN, USA;
- Department of Vascular Surgery, Baylor Scott and White Heart and Vascular Hospital Dallas, Dallas, TX, USA;
- Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA;
- Department of Neurosurgery, Henry Ford Medical Group, Detroit, MI, USA; Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA;
- Neurology Section, Jesse Brown VA Medical Center, Chicago, IL, USA; and Department of Pain Management, Cleveland Clinic, Cleveland, OH, USA

For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please see the journal's Guide

Source(s) of financial support: The high-freQUEncy nerve block for poST amoutation pain (QUEST) study and publication of this article were funded by Neuros Medical



**Amputee** 

Pain

Other Pain

**Indications?** 

**FDA PMA** 

Clearance

August, 2024

16

# Thank You!



